Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy
about
Methodological requirements for valid tissue-based biomarker studies that can be used in clinical practiceEpidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancerMolecular oncology testing in resource-limited settings.Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues.Development and use of integral assays in clinical trialsLeveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug developmentA Buffered Alcohol-Based Fixative for Histomorphologic and Molecular ApplicationsBiomarkers in precision therapy in colorectal cancer.Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer.The national biomarker development alliance: confronting the poor productivity of biomarker research and development.Review of methods for determination of total protein and peptide concentration in biological samples.Developments in biospecimen research.Reverse transcription-polymerase chain reaction molecular testing of cytology specimens: Pre-analytic and analytic factors.Translating pharmacodynamic biomarkers from bench to bedside: analytical validation and fit-for-purpose studies to qualify multiplex immunofluorescent assays for use on clinical core biopsy specimens.Molecular pathology as the driving force for personalized oncology.Veterinary and human biobanking practices: enhancing molecular sample integrity.Improving the state of the science of immunohistochemistry: the Histochemical Society's standards of practice.Determination of phosphorylated proteins in tissue specimens requires high-quality samples collected under stringent conditions.Histomorphological and Molecular Assessments of the Fixation Times Comparing Formalin and Ethanol-Based Fixatives.Biomarker measurements: how far have we come and where are we heading?
P2860
Q26996340-C796215F-DCB5-44FC-B299-A6B5D0A8BF0AQ28084216-DCA6D97E-D021-4D3D-8BD3-A1A10443B0C4Q34409732-21FD3C37-BF2B-4F78-95C7-05576581304EQ35574950-CB40DB89-FF1F-4370-AE94-B54874CC1DDEQ35838558-06E2882D-906E-4076-BC6B-A9DCE4A788BEQ35838562-94F6FF26-0929-4F24-A29E-32635E39B953Q37062250-72711557-D35C-4D4C-B361-A04A9163385DQ37609130-0E0519D5-2E8D-484B-B0DE-93D21196B771Q37733727-5DC01CC3-79D3-4275-8245-BC3894436591Q38270923-C1C5951D-6D2E-40DA-B310-C1CD0F1214AFQ38340369-1929DCA5-8B00-4D56-92C9-3DED581A1EC6Q38390425-A8A5A1AC-52BC-4C35-9FAF-41B074493865Q38895865-D422C6C1-265E-4FC2-B975-1B34DECEBCD7Q38963126-8ACB3330-E665-473B-AAAB-01F045AAEBFBQ39501574-F816B3C3-9B32-4E41-AF7A-BCF9B9E1D9F2Q40150160-1E5C9609-B74D-4610-9178-BB092AD5BA6FQ42965900-7F8941BD-00B7-43D4-8357-C9E7B68E397BQ46477181-EEB43452-ED65-4CD9-AC4F-E20434EEE471Q47416520-0EEFFAEF-88ED-4351-816D-AB4C8D4E55DDQ51322752-4E4E2346-B641-47B2-B6C1-4C523590F96E
P2860
Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Impact of preanalytic factors ...... for directing patient therapy
@ast
Impact of preanalytic factors ...... for directing patient therapy
@en
type
label
Impact of preanalytic factors ...... for directing patient therapy
@ast
Impact of preanalytic factors ...... for directing patient therapy
@en
prefLabel
Impact of preanalytic factors ...... for directing patient therapy
@ast
Impact of preanalytic factors ...... for directing patient therapy
@en
P2860
P1476
Impact of preanalytic factors ...... for directing patient therapy
@en
P2093
Lawrence D True
Sunil S Badve
P2860
P304
P356
10.1158/1078-0432.CCR-11-2204
P407
P577
2012-03-01T00:00:00Z